In 2023, the SELECT trial published results that changed how cardiologists think about GLP-1 medications. Semaglutide reduced major adverse cardiovascular events (MACE) — heart attacks, strokes, and cardiovascular death — by 20% in people with obesity but without diabetes. This is a landmark finding.
If you have established cardiovascular disease, or significant cardiovascular risk factors (high BP, high cholesterol, smoking history, family history), GLP-1 is not just a weight loss tool — it's a cardiovascular protective medication. This changes the conversation about how long to use it.
GLP-1 cardiovascular benefits are additive to exercise — not a replacement for it. Cardiorespiratory fitness (VO2 max) remains one of the strongest independent predictors of longevity and cardiac health. Medication plus exercise is better than either alone.
Getting 100g+ of protein daily on a reduced appetite is hard. Strategic timing makes it more achievable — and more effective for muscle preservation.
Medication helps with appetite. But the mental skills for sustainable weight management — resilience, flexibility, self-compassion — must be built intentionally.
People who share their journey with a community — online or in person — consistently achieve better outcomes. Here's why, and where to find yours.